Track record · closed signal

Innoviva Inc (INVA) — closed signal from July 1, 2026

Partial Published before the outcome was known, scored automatically when the window closed on September 29, 2026 — -6.9% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted
$22.67 Published $27.43 Target $21.11 Window close $22.89 Peak
$22.00 – $23.00Entry zone — fair-value band
$22.67Published — price the day we called it
$27.43Target — the price the thesis aimed for
$22.89Peak — highest point inside the window, not a realized return
$21.11Window close — end-of-window price, context only

What happened

Partial

Reached 5% of the predicted growth at its peak, without hitting the target.

At window close
-6.9%
realized, from the publication price to the last close inside the window
Peak gain
+1%
peak, from the publication price — not a realized return
S&P 500, same window
+2.7%
SPY over the identical days, dividend-adjusted
Window close
$21.11
last close inside the window, ended September 29, 2026
Peak price
$22.89
peak on July 1, 2026 — not a realized return
Days to target
—

The thesis — published July 1, 2026

Predicted growth
+21%
over the measurement window
Target price
$27.43
the price the thesis aimed for
Entry zone
$22.00 – $23.00
the fair-value band we waited for
Price at publication
$22.67
published July 1, 2026
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Innoviva looks like a selective value play: it does not move with the market much, has a solid balance sheet, and has beaten earnings expectations before. Nortiva Bio's launch gives a real business reason to own the stock related to long-acting oral treatments. Short-term rebound signs exist, but very light trading and questions about earnings strength keep confidence limited.

Primary drivers

  • Nortiva Bio launch provides a clear business catalyst tied to oral therapies
  • Low valuation plus cash on hand helps limit downside risk
  • Stock is oversold but shows signs of price improvement for a rebound
  • Very low liquidity and uncertain earnings quality reduce confidence

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals